Development

Smartphones and Intelligent Socks to Help Prevent Diabetic Amputations

Diabetic neuropathy is a type of nerve damage associated with the development of foot ulcers in patients with diabetes. Resulting from anatomical deformation, excessive pressure and poor blood supply, it affects over 130 million individuals worldwide. It is also the leading cause of amputation, costing the United States economy alone more than $10 billion annually.

Diabetic patients are encouraged to get regular checkups to monitor for the increased pressure and ulceration that can eventually require amputation. However, ulcers are only diagnosed after they occur, meaning that patients require healing time, which dramatically increases healthcare costs.

Members of the BioDesign: Medical Innovation program, created by The Hebrew University of Jerusalem and its affiliated Hadassah Medical Center, set out to solve this problem.

"This is a significant medical problem that affects the lives of millions. We thought there must be a way to avoid these wounds altogether," said Danny Bavli, the group's lead engineer.

To address this challenge, Bavli partnered with Sagi Frishman and Dr. David Morgenstern, a leading orthopedic surgeon at Hadassah Medical Center. Together with other members of the Hebrew University BioDesign group, they developed SenseGO, a machine-washable sock containing dozens of micro-fabricated pressure sensors.

With SenseGO, changes in pressure due to incorrect posture, anatomical deformation or ill-fitting shoes are registered as electrical signals that are relayed to a smartphone app, which in turn informs the patient of developing risk.

Prof. Yaakov Nahmias, BioDesign program director, said: "This is a classic mobile health approach. By giving patients and their families the tools they need to prevent the development of ulcers, we can dramatically reduce health care costs related to diabetes."

Other members of the BioDesign SenseGO team included Inbal Boxerman and Yael Hadar, MBA students at The Hebrew University of Jerusalem.

BioDesign: Medical Innovation is a multi-disciplinary, team-based approach to medical innovation, created by the Hebrew University of Jerusalem and its affiliated Hadassah Medical Center. Sponsored by Boston Scientific and the Terumo Medical Corporation, the program takes outstanding medical fellows, bioengineering and business graduate students, and tutors them in the science and practice of bringing a medical innovation to the market. The program is directed by Prof. Yaakov Nahmias, director of the Alexander Grass Center for Bioengineering at the Hebrew University of Jerusalem, and Prof. Chaim Lotan, director of the Heart Institute at Hadassah Medical Center.

The innovations produced by the Biodesign program participants are commercialized by Yissum, the technology transfer company of the Hebrew University of Jerusalem, and Hadasit, the technology transfer company of the Hadassah Medical Center.

Most Popular Now

Aridhia Announces Expansion as it U…

A Scottish clinical and translational informatics company has announced it is part of a consortium selected to deliver a digital research environment based on its Analyti...

Read more

Smartphones and Wearable Devices co…

RADAR-CNS (Remote assessment of disease and relapse - Central Nervous System), a major new research programme supported by the Innovative Medicines Initiative (IMI) start...

Read more

Person-Centered App Helps Women wit…

The face-to-face meetings between the patient and the care provider might be successfully complemented with person-centered e-support. A preliminary evaluation of breast ...

Read more

Patientrack Recognised as One of 'T…

UK healthcare technology company Patientrack has been recognised as providing one of the best eHealth solutions anywhere in Europe, in an EU competition focussed on healt...

Read more

Mobile Technology: Is the NHS Closi…

Opinion Article by Steve Carvell, head of healthcare at CommonTime. Technology skills are in higher demand than ever. Look across any vertical and developers who can cre...

Read more

Philips and SURFsara Team up to Pro…

Royal Philips (NYSE: PHG; AEX: PHIA) and SURFsara (a subsidiary of the SURF cooperation), the leading Dutch high-performance supercomputing and data infrastructure provid...

Read more

Innovations in Neuroimaging Lead to…

The current special issue of Technology and Innovation, Journal of the National Academy of Inventors, Volume 18, Number 1 (all open access), is devoted to the evolution o...

Read more

Merck in Agreement with HAPPYneuron…

Merck, a leading science and technology company, announced today that the company has entered into an agreement with HAPPYneuron, a subsidiary of SBT Group of France, in ...

Read more

Future Health Index 2016

Royal Philips (NYSE: PHG, AEX: PHIA) today launched the results of the first edition of its Future Health Index (FHI), an extensive international study which explores how...

Read more

New Digital Centre to Help Improve …

A new centre for digital innovation which could transform the way mental health care is provided will be launched today. The Centre for Translational Informatics (CTI) is...

Read more

Patients and Medical Staff Value UM…

Patients and medical staff of the Arrixaca Hospital Onco-Hematological Day Hospital have valued very positively the implementation of UMANICK Identity for Health. This is...

Read more

Smart Sensors and Innovation Are th…

Royal Philips (NYSE: PHG; AEX: PHIA) has announced the Philips Sonicare FlexCare Platinum Connected, its latest innovation that uses Smart Sensor technology to help consu...

Read more

Digest Newsletter

Subscribe to our weekly Newsletter and stay updated on the latest eHealth News. Subscribe now, it's free!
© eHealthNews.eu 2006 - 2016